SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Salven, P. Articles by Joensuu, H. Search for Related Content PubMed PubMed Citation Articles by Salven, P. Articles by Joensuu, H. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 December 2000, Vol. 96, No. 12, pp. 3712-3718 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Petri Salven, Arto Orpana, Lasse Teerenhovi, and Heikki Joensuu From the Department of Cell Biology, New York University School of Medicine, New York, NY; and the Departments of Oncology and Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland. High serum concentrations of vascular endothelial growth factor (S-VEGF) and basic fibroblast growth factor (S-bFGF) are associated with unfavorable clinical characteristics in cancer. The combined effect of S-VEGF and S-bFGF on the survival of 200 patients with non-Hodgkin lymphoma (NHL) was studied. High S-VEGF and S-bFGF at diagnosis were associated with poor survival with the medians, the highest tertiles, or the highest quartiles as the cutoff values. The highest prognostic power was obtained when S-VEGF and S-bFGF were examined as a combination. Patients who had both S-VEGF and S-bFGF within the highest quartiles had only a 21% 5-year survival rate in contrast to a 64% 5-year survival rate among patients with both factors within the 3 lowest quartiles (P < .0001). Simultaneous elevation of S-VEGF and S-bFGF was associated with poor survival in different grades of lymphomas and in the largest histologic subgroup, the large-cell diffuse and immunoblastic lymphomas. S-VEGF (relative risk [RR], 1.83; P = .019) and S-bFGF (RR, 2.02; P = .0049) had independent influences on survival in multivariate models when tested together with the components of the International Prognostic Index (IPI). Patients with both S-VEGF and S-bFGF within the highest quartiles had nearly 3 times higher risk for death (RR, 2.90; 95% confidence interval [CI], 1.56-5.40; P = .0008) than the rest of the patients. This RR was higher than the relative risks associated with any of the components of the IPI in the same model. The authors conclude that the combination of S-VEGF and S-bFGF is a powerful prognostic variable in NHL. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Delmonte, M. Ghielmini, and C. Sessa Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas Oncologist, May 1, 2009; 14(5): 511 - 525. [Abstract] [Full Text] [PDF] A. Tzankov, S. Heiss, S. Ebner, W. Sterlacci, G. Schaefer, F. Augustin, M. Fiegl, and S. Dirnhofer Angiogenesis in nodal B cell lymphomas: a high throughput study J. Clin. Pathol., May 1, 2007; 60(5): 476 - 482. [Abstract] [Full Text] [PDF] I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF] A. Koster, J. H.J.M. van Krieken, M. A. MacKenzie, M. Schraders, G. F. Borm, J. A.W.M. van der Laak, W. Leenders, K. Hebeda, and J. M.M. Raemaekers Increased Vascularization Predicts Favorable Outcome in Follicular Lymphoma Clin. Cancer Res., January 1, 2005; 11(1): 154 - 161. [Abstract] [Full Text] [PDF] E. S. Wang, J. Teruya-Feldstein, Y. Wu, Z. Zhu, D. J. Hicklin, and M. A. S. Moore Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo Blood, November 1, 2004; 104(9): 2893 - 2902. [Abstract] [Full Text] [PDF] A. Younes, B. Pro, M. J. Robertson, I. W. Flinn, J. E. Romaguera, F. Hagemeister, N. H. Dang, P. Fiumara, E. M. Loyer, F. F. Cabanillas, et al. Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease Clin. Cancer Res., August 15, 2004; 10(16): 5432 - 5438. [Abstract] [Full Text] [PDF] R. Bieker, T. Padro, J. Kramer, M. Steins, T. Kessler, S. Retzlaff, F. Herrera, J. Kienast, W. E. Berdel, and R. M. Mesters Overexpression of Basic Fibroblast Growth Factor and Autocrine Stimulation in Acute Myeloid Leukemia Cancer Res., November 1, 2003; 63(21): 7241 - 7246. [Abstract] [Full Text] [PDF] M. Capillo, P. Mancuso, A. Gobbi, S. Monestiroli, G. Pruneri, C. Dell'Agnola, G. Martinelli, L. Shultz, and F. Bertolini Continuous Infusion of Endostatin Inhibits Differentiation, Mobilization, and Clonogenic Potential of Endothelial Cell Progenitors Clin. Cancer Res., January 1, 2003; 9(1): 377 - 382. [Abstract] [Full Text] [PDF] T. Ruotsalainen, H. Joensuu, K. Mattson, and P. Salven High Pretreatment Serum Concentration of Basic Fibroblast Growth Factor Is a Predictor of Poor Prognosis in Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1492 - 1495. [Abstract] [Full Text] [PDF] S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia Blood, October 16, 2002; 100(9): 3344 - 3351. [Abstract] [Full Text] [PDF] H. Joensuu, A. Anttonen, M. Eriksson, R. Makitaro, H. Alfthan, V. Kinnula, and S. Leppa Soluble Syndecan-1 and Serum Basic Fibroblast Growth Factor Are New Prognostic Factors in Lung Cancer Cancer Res., September 15, 2002; 62(18): 5210 - 5217. [Abstract] [Full Text] [PDF] R. S. Go, A. L. Horstman, K. Neben, and H. Goldschmidt Correspondence re: K. Neben et al., High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma. Clin. Cancer Res., 7: 2675-2681, 2001. Clin. Cancer Res., August 1, 2002; 8(8): 2750 - 2751. [Full Text] [PDF] M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells Blood, May 1, 2002; 99(9): 3383 - 3389. [Abstract] [Full Text] [PDF] R. M. Tuttle, M. Fleisher, G. L. Francis, and R. J. Robbins Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1737 - 1742. [Abstract] [Full Text] [PDF] F. J. Giles The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 32 - 39. [Abstract] [Full Text] [PDF] O. Sezer, C. Jakob, K. Niemoller, R. T.P. Poon, S.-T. Fan, and J. Wong Angiogenesis in Cancer J. Clin. Oncol., July 1, 2001; 19(13): 3299 - 3301. [Full Text] S. Monestiroli, P. Mancuso, A. Burlini, G. Pruneri, C. Dell'Agnola, A. Gobbi, G. Martinelli, and F. Bertolini Kinetics and Viability of Circulating Endothelial Cells As Surrogate Angiogenesis Marker in an Animal Model of Human Lymphoma Cancer Res., June 1, 2001; 61(11): 4341 - 4344. [Abstract] [Full Text] [PDF] R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020